Meeting
2012 ASCO Annual Meeting
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
Authors
Stephanie Heon
Dana-Farber Cancer Institute, Boston, MA
Stephanie Heon , Mizuki Nishino , Sarah B. Goldberg , Jennifer Porter , Lecia V. Sequist , David Michael Jackman , Bruce E. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7525)
DOI
10.1200/jco.2012.30.15_suppl.7525
Abstract #
7525
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size.
First Author: Sai-Hong Ignatius Ou
Poster
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
First Author: Julien Mazieres
Poster
2014 ASCO Annual Meeting
Clinical impact of gastric acid suppressing medication use on the efficacy of elrotinib and gefitinib in patients with advanced non-small cell lung cancer harboring EGFR mutations.
First Author: Yoshitaka Zenke
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu